BCAA supplementation has also been demonstrated to reduce the risk of hepatocellular carcinoma in patients with liver cirrhosis[41], decrease proliferation[42] and endothelial cell tubule formation in hepatocellular carcinoma cells, decrease neovascularisation in the liver[43], and reduce angiogenic markers such as VEGF and Tie-2[43, 44]. This evidence concerns the gene TEK and cirrhosis of liver.